Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $74.46 USD
Change Today -1.74 / -2.28%
Volume 4.7M
MDT On Other Exchanges
As of 8:04 PM 02/5/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

20 On Hatch

Lower Hatch Street

Dublin, 2


Phone: 353 1 438 1700


Medtronic plc engages in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life. The company serves hospitals, physicians, clinicians, and patients in approximately 160 countries worldwide. Segments The company operates in the following segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group, and Diabetes Group. Cardiac and Vascular Group Cardiac Rhythm and Heart Failure Disease Management (CRHF) The CRHF division develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. The company’s products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRHF devices, and an integrated health solutions business. The following are the principal products and services offered by the CRHF division: Implantable Cardiac Pacemakers (Pacemakers): The company’s latest generation of pacemaker systems is the Advisa and Revo MRI SureScan models, which have received the United States Food and Drug Administration (U.S. FDA) approval, and the Advisa and Ensura MRI SureScan models, as well as the Micra Transcatheter Pacing System, which have all received Conformité Européene (CE) Mark approval. Implantable Cardioverter Defibrillators (ICDs): The company’s latest generation ICD is the Evera MRI SureScan, the first ICD system with CE Mark approval for full-body MRI scans. Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps): The company’s CRT-Ds is the Viva/Brava family with Attain Performa quadripolar lead and features a new algorithm, called AdaptivCRT, which improves heart failure patients' response rate to CRT-D therapy. AF Products: The company’s portfolio of AF products includes the Arctic Front Advance Cardiac Cryoballoon System designed for pulmonary vein isolation in the treatment of patients with drug refractory paroxysmal AF. Additionally, the company has a second-generation CE Mark approved Phased RF System, PVAC Gold, which uses duty cycled, phased radio frequency energy for the treatment of symptomatic paroxysmal persistent and long-standing persistent AF. Diagnostics and Monitoring Devices: The company’s Reveal LINQ is its newest Insertable Cardiac Monitor (ICM) System. The system is used to record the heart’s electrical activity before, during, and after transient symptoms such as syncope and palpitations to assist in diagnosis. Services and Solutions: The company’s Cardiocom products and services include remote monitoring and patient-centered software to enable care coordination and specialized telehealth nurse support. The company’s TYRX products include the Absorbable Antibacterial Envelope and the TYRX Neuro Absorbable Antibacterial Envelope, which are designed to stabilize electronic implantable devices and help prevent infection associated with implantable pacemakers, defibrillators, and spinal cord neurostimulators. Coronary and Structural Heart Disease Management (CSH) The CSH division includes therapies to treat coronary artery disease (CAD), and heart valve disorders. The company’s products include coronary stents and related delivery systems, including a line of balloon angioplasty catheters, guide catheters, guide wires, diagnostic catheters, and accessories, as well as products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products. The following are the principal products offered by the CSH division: Transcatheter Heart Valves (TCVs): The company’s latest generation TCVs include the CoreValve family of aortic valves. CoreValve, which is the only TCV system shown to be superior to open-heart surgery, has received the U.S. FDA approval for extreme and high risk patients. Percutaneous Coronary Intervention (PCI): The company’s latest generation PCI stent products include its Resolute Integrit


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $74.46 USD -1.74

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $153.47 USD +0.03
AbbVie Inc $53.12 USD -3.64
Allergan plc $273.80 USD +1.35
Amgen Inc $145.04 USD -4.87
GlaxoSmithKline PLC 1,401 GBp -11.50
View Industry Companies

Industry Analysis


Industry Average

Valuation MDT Industry Range
Price/Earnings 43.6x
Price/Sales 4.2x
Price/Book 2.0x
Price/Cash Flow 27.9x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MEDTRONIC PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at